Bogdana Schmidt, MD, MPH, shares why gemcitabine intravesical system is a game changer in NMIBC

Bogdana Schmidt, MD, MPH, discusses the recently FDA-approved gemcitabine intravesical system (Inlexzo; formerly TAR-200) for adult patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

For more, see https://www.urologytimes.com/view/fda-approves-gemcitabine-intravesical-system-for-bcg-unresponsive-high-risk-nmibc

Видео Bogdana Schmidt, MD, MPH, shares why gemcitabine intravesical system is a game changer in NMIBC канала Urology Times